|1.||Aroniadou-Anderjaska, Vassiliki: 4 articles (04/2015 - 02/2011)|
|2.||Braga, Maria F M: 4 articles (04/2015 - 02/2011)|
|3.||Apland, James P: 4 articles (04/2015 - 02/2011)|
|4.||Figueiredo, Taiza H: 4 articles (04/2015 - 02/2011)|
|5.||Prager, Eric M: 2 articles (04/2015 - 02/2015)|
|6.||Qashu, Felicia: 2 articles (01/2013 - 02/2011)|
|7.||Brennan, Timothy J: 2 articles (10/2007 - 10/2006)|
|8.||Sang, C N: 2 articles (07/2004 - 09/2000)|
|9.||Chappell, A S: 2 articles (07/2004 - 09/2000)|
|10.||Gilron, I: 2 articles (09/2001 - 09/2000)|
02/01/2015 - "In the present study, we examined whether the protection against nerve agent-induced seizures and neuropathology conferred by LY293558 translates into protection against pathophysiological alterations in the basolateral amygdala (BLA) and the development of anxiety, which is the most prevalent behavioral deficit resulting from exposure. "
02/01/2015 - "Along with our previous findings, the present data demonstrate the remarkable efficacy of LY293558 in counteracting nerve agent-induced seizures, neuropathology, pathophysiological alterations in the BLA, and anxiety-related behavioral deficits."
01/01/2013 - "There was good correspondence between the time course of seizure suppression by LY293558 and the brain levels of the compound."
02/01/2011 - "LY293558 is a potential new emergency treatment for nerve agent exposure that can be expected to be effective against seizures and brain damage even with late administration."
02/01/2011 - "Therefore, we tested whether LY293558 is effective against soman-induced seizures and neuropathology, when administered 1 h after soman exposure, in rats. "
10/01/2006 - "LY293558 was most effective for evoked pain when administered intrathecally. "
09/01/2001 - "By January 2000, LY-293558 was undergoing phase II trials for pain ."
10/01/2007 - "After plantar incision, epidural tezampanel decreased the median guarding pain score, increased the heat withdrawal latency and increased the mechanical withdrawal threshold indicating analgesic effects. "
10/01/2007 - "The effects of epidural tezampanel on the cumulative pain scoring, based on guarding, the withdrawal threshold to von Frey filament application, and the withdrawal latency to heat, were measured. "
10/01/2007 - "The effects of epidural tezampanel on pain-related behaviors in rats that underwent plantar incision were also studied. "
10/01/2006 - "Parenteral, intrathecal, or intraplantar administration of LY293558 was tested against the mechanical hyperalgesia that characterizes the model. "
10/01/2006 - "The purpose of this study was to assess the efficacy of a non-NMDA receptor antagonist LY293558 on mechanical hyperalgesia after plantar incision in the rat. "
12/01/2012 - "This study evaluated the effects of an oral prodrug to tezampanel, a selective α-amino-3-hydroxy-5-methly-4-isoxazole-proprionic acid/kainate receptor antagonist, on intradermal capsaicin-induced pain and hyperalgesia. "
11/01/1998 - "The effects of the competitive AMPA-KA antagonist LY293558 in two types of experimental pain in human volunteers, brief pain sensations in normal skin, and mechanical allodynia-pinprick hyperalgesia were studied after the injection of intradermal capsaicin. "
11/01/1998 - "AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans."
|4.||Migraine Disorders (Migraine)
07/01/2004 - "We therefore tested LY293558 in acute migraine. "
07/01/2004 - "The efficacy and safety results of LY293558 in this small migraine proof of concept trial, together with supportive preclinical data, provide evidence for a potential role of nonvasoactive AMPA/KA antagonists in treating migraine. "
07/01/2004 - "We conducted a randomized, triple-blind, parallel-group, double-dummy, multicentre trial of 1.2 mg/kg intravenous (IV) LY293558, 6 mg subcutaneous (SC) sumatriptan, or placebo in the treatment of acute migraine. "
07/01/2004 - "LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine."
07/01/2004 - "LY293558 and sumatriptan were superior to placebo (P < 0.01 for all comparisons) on all other measures of improvement in pain and migraine associated symptoms. "
|5.||Anxiety Disorders (Anxiety Disorder)
|1.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|3.||Kainic Acid Receptors (Kainate Receptor)
|6.||AMPA Receptors (AMPA Receptor)
|7.||Kainic Acid (Kainate)
|10.||Dizocilpine Maleate (Dizocilpine)